ABL1 and chronic myelogenous leukemia, BCR-ABL1 positive: LNP treatment of CD34+ primary bone marrow cells from BCR-ABL-positive CML patients showed a higher reduction in BCR-ABL than in healthy donors, suggesting that the LNPs are able to effectively target diseased cells over normal healthy bone marrow cells.